Technical Analysis for CERO - CERo Therapeutics Holdings, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.21 | -2.81% | -0.03 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | -2.81% | |
Narrow Range Bar | Range Contraction | -2.81% |
Free Daily (Stock) Chart Reading
- Earnings date: Unknown
CERo Therapeutics Holdings, Inc. Description
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ("CER-T"). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ("CAR-T") cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2024 for hematological malignancies.
Classification
Sector: Other
Industry: Other
Keywords: Cancer Solid Tumors Immune System Immunotherapy Treatment Of Cancer Tumor Cancer Immunotherapy Cell Therapy Lymphoma Virotherapy Hematological Malignancies Adoptive Cell Transfer T Cells Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Therapy Car T Cell Treating Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12.8 |
52 Week Low | 1.18 |
Average Volume | 1,359,076 |
200-Day Moving Average | 8.19 |
50-Day Moving Average | 1.99 |
20-Day Moving Average | 1.45 |
10-Day Moving Average | 1.34 |
Average True Range | 0.23 |
RSI (14) | 21.26 |
ADX | 25.91 |
+DI | 29.75 |
-DI | 22.57 |
Chandelier Exit (Long, 3 ATRs) | 1.40 |
Chandelier Exit (Short, 3 ATRs) | 1.87 |
Upper Bollinger Bands | 1.79 |
Lower Bollinger Band | 1.12 |
Percent B (%b) | 0.13 |
BandWidth | 45.91 |
MACD Line | -0.28 |
MACD Signal Line | -0.33 |
MACD Histogram | 0.0449 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.33 | ||||
Resistance 3 (R3) | 1.33 | 1.30 | 1.31 | ||
Resistance 2 (R2) | 1.30 | 1.27 | 1.29 | 1.30 | |
Resistance 1 (R1) | 1.25 | 1.25 | 1.23 | 1.25 | 1.30 |
Pivot Point | 1.22 | 1.22 | 1.21 | 1.21 | 1.22 |
Support 1 (S1) | 1.17 | 1.19 | 1.15 | 1.17 | 1.12 |
Support 2 (S2) | 1.14 | 1.17 | 1.13 | 1.11 | |
Support 3 (S3) | 1.09 | 1.14 | 1.11 | ||
Support 4 (S4) | 1.09 |